-- 据周二提交给澳大利亚证券交易所的文件显示，Clinuvel Pharmaceuticals（ASX：CUV）表示，公司正与美国证券交易委员会（SEC）合作，就其美国存托凭证（ADR）项目在纳斯达克股票市场上市的注册声明草案进行磋商。 该公司已收到美国证券交易委员会的四轮意见征询，预计审查流程将在本财年结束前完成。根据文件，公司计划将ADR项目从一级升级至二级，并以修订后的股票代码“CUVL”在纳斯达克上市。 该公司在文件中补充道，此次上市仍需获得监管机构的批准以及满足纳斯达克的相关要求，其成功与否以及上市时间均无法保证。
Related Articles
Asia
Bio Port Korea Returns to Profit in Q1
Bio Port Korea (KOSDAQ:188040) posted first-quarter net income of 710 million won, rebounding from a net loss of 34 million won a year earlier, according to a Tuesday filing with the Korea Exchange.The South Korean health functional foods company's sales revenue jumped 27% year over year to 21.4 billion won from 16.9 billion won.Shares of Bio Port Korea rose more than 2% in recent trade.
$KOSDAQ:188040
Asia
Yanghe Brewery 2025 Profit Falls 67%, Revenue Slips 33%
Jiangsu Yanghe Brewery (SHE:002304) posted 2025 attributable net profit of 2.21 billion yuan, down 67% from 6.67 billion yuan the previous year.Earnings per share fell to 1.4644 yuan from 4.4299 yuan, according to a Tuesday filing with the Shenzhen bourse.The liquor company's revenue declined 33% year over year to 19.2 billion yuan from 28.9 billion yuan.
$SHE:002304
Asia
Resolution Minerals Produces Tungsten Trioxide Concentrates Via Preliminary Gravity Separation Test Work, Shares Up 4%
Resolution Minerals (ASX:RML) produced concentrates of 52.3% tungsten trioxide via preliminary gravity separation test work on tungsten composite samples, assaying 1.85% grade of tungsten trioxide, from stockpiles at the Johnson Creek mill site, sourced from the historical mining at the Golden Gate tungsten mine in Idaho, according to a Tuesday Australian bourse filing.Heavy liquid separation scoping tests on the tungsten composite samples achieved a grade of 52.3% of tungsten trioxide with a recovery of 75.5%.Its shares rose 4% in recent trading on Tuesday.
$ASX:RML